Invega Sustenna

Paliperidone palmitate

Treatment of schizophrenia & prevention of recurrence of symptoms of schizophrenia. Schizoaffective disorder as monotherapy & adjunct to mood stabilizers or antidepressants.

IM Schizophrenia Initially 150 mg on day 1 & 100 mg 1 wk later, both administered in deltoid muscle. Mthly maintenance dose: 75 mg, may be adjusted w/in range of 25-150 mg, administered in either deltoid or gluteal muscle. Schizoaffective disorder Initially 150 mg on day 1 & 100 mg 1 wk later, both administered in deltoid muscle. Mthly maintenance dose: W/in range of 50-150 mg, administered in either deltoid or gluteal muscle. Mild renal impairment (CrCl ≥50 to <80 mL/min) Initially 100 mg on day 1 & 75 mg 1 wk later, both administered in deltoid muscle. Followed by mthly inj of 50 mg, may be adjusted w/in range of 25-100 mg, administered in either deltoid or gluteal muscle.

Hypersensitivity to paliperidone & risperidone.

Discontinue use if hypersensitivity reactions occur; signs or symptoms of NMS or tardive dyskinesia develop. Not to be inj in divided doses, intravascularly or SC. Patients w/ history of cardiac arrhythmias, congenital long QT syndrome; known CV & cerebrovascular disease or conditions predisposing to hypotension; seizures or other conditions potentially lowering seizure threshold; clinically significant low WBC or drug-induced leukopenia/neutropenia; risk factors for VTE; Parkinson's disease & dementia w/ Lewy bodies. Hyperglycemia, DM & exacerbation of preexisting diabetes; wt gain; priapism; disruption of the body's ability to reduce core temp; antiemetic effect; intraoperative floppy iris syndrome. Concomitant use w/ psychostimulants eg, methylphenidate; drugs prolonging QT interval. May interfere w/ activities requiring mental alertness (eg, driving or operating machinery) & may have visual effects. Not recommended in moderate or severe renal impairment (CrCl <50 mL/min). Severe hepatic impairment. Pregnancy. Not to be used during lactation. Childn <18 yr. Elderly w/ dementia.

Upper resp tract infection; agitation, insomnia, nightmare; akathisia, dizziness, extrapyramidal disorder, headache, somnolence/sedation; HTN; upper abdominal pain, constipation, diarrhea, dry mouth, nausea, toothache, vomiting; pain in extremity; asthenia, fatigue, inj site pain; increased wt.

Concomitant use w/ drugs prolonging QT interval; centrally-acting drugs & alcohol; risperidone or oral paliperidone. May antagonize effect of levodopa & other dopamine agonists. Additive effect to other agents w/ potential to induce orthostatic hypotension. Decreased mean steady-state C_max & AUC w/ carbamazepine. Emergence of extrapyramidal symptoms w/ psychostimulants eg, methylphenidate.

Antipsychotics

N05AX13 - paliperidone ; Belongs to the class of other antipsychotics.

Rx